Hubungan Kadar Trombosit dan Neutrofil antara Kanker Ovarium Tipe Epitelial Rekuren dan Nonrekuren
Abstract
Tujuan: Menganalisis hubungan kadar trombosit dan neutrofil terhadap rekurensi kanker ovarium.
Metode: Penelitian observasi case control. Data dan sampel darah diambil dari perempuan penderita kanker ovarium tipe epitelial rekuren dan tidak rekuren sebanyak 117 orang. Data yang diambil berupa usia, paritas, status menopause, serta hasil laboratorium darah rutin saat sebelum kemoterapi dan pasca kemoterapi 6 kali. Data diuji dengan analisis independent sample t test, uji Mann Whitney, analisis korelasi, serta analisis regresi logistik biner.
Hasil: Terdapat hubungan yang signifikan antara kadar trombosit dan neutrofil terhadap rekurensi kanker ovarium (p<0,05). Persamaan regresi logistik y= -1,488 + 1,132 x trombosit pasca operasi + 0,961 x Neutrofil. Nilai OR (95% CI) kadar trombosit sebesar 3,102 (1,357–7,092). Tidak terdapat hubungan yang signifikan antara leukosit dan hemoglobin dengan rekurensi kanker ovarium (P>0,05).
Kesimpulan: Kadar trombosit dan netrofil memiliki korelasi terhadap rekurensi kanker ovarium. Kadar leukosit dan hemoglobin tidak berkaitan dengan rekurensi kanker ovarium.
Correlation between Platelet and Neutrophil Levels in Recurrence Epithelial Ovarian Cancer
Abstract
Objective: To analyze the relationship between platelet and neutrophil levels on ovarian cancer recurrence
Methods: Case-control observation research. Data and blood samples were taken from 117 women with recurrent and non-recurrent epithelial ovarian cancer patients. Primary data taken were age, parity, menopausal status, laboratory results of routine blood examination carried out before and after chemotherapy six times. Data were tested by independent sample t-test, Mann Whitney test, correlation analysis, and binary logistic regression analysis.
Results: There was a statistically significant relationship between platelets and neutrophils with ovarian cancer recurrence (p<0.05). The logistic regression equation y= -1.488 + 1.132 x postoperative platelets + 0.961 x neutrophils. The OR (95% CI) for platelet levels was 3.102 (1.357–7.092). There was no significant relationship between leukocytes and hemoglobin with ovarian cancer recurrence (P>0.05).
Conclusion: Platelet and neutrophil levels are associated with ovarian cancer recurrence. Leukocyte and hemoglobin levels were not associated with ovarian cancer recurrence.
Key words: ovarian cancer, chemotherapy, recurrence, platelets
Keywords
Full Text:
PDFReferences
Siegel, R. L., Miller, K. D. and Jemal, A. 2018. Cancer statistics, 2018,” CA: A Cancer Journal for Clinicians. 2018. doi: 10.3322/caac.21442.
Kementerian Kesehatan. Buletin Jendela Data dan Informasi Kesehatan. Situasi Penyakit Kanker,” Pusat Data dan Informasi. 2015. doi: ISSN 2088 - 270X.
Salani, R., Neuberger, I., Kurman, R.J., dan Bristow, R.E. Chang, H.W., Wang, T.L., dan Shinh, L.M. Expression of extracellular matrix proteins in ovarian serous tumors. Int J. Gynecol pathol. 2007; 26(2): 141-146.
Hu, Z., Li, Z., Ma, Z., Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nature genetics. 2020; 52: 701-708.
Allensworth, S. K. et al. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer, 2014; 130(3), pp. 499–504. doi: 10.1016/j.ygyno.2013.05.038.Evaluating.
Yanti DAM, Sulistianingsih A. Determniant Factors of Ovarium Cancer in Abdoel Moelok Hospital Lampung in 2015. Ejournal UMM. 2016. Volume 2 (7).
Cozzi, G.D., Samuel, J.M., Fadiel, A.B. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer, 2016; 16:612.
Gajjar, K, Ogden, G, Mujahid, MI, dan Razyi, K. Research Article: Symptoms and Risk Factors of Ovarian Cancer: A Survey in Primary Care. International Scholarly Research Network (ISRN) Obstetrics and Gynecology. [serial online] 2012:1-6.
Miller, A.B. Morgan, L.L., Udasin, I., Davis, D.L. Cancer epidemiology update, following the 2011 IARC evaluation of radiofrequency electromagnetic fields (Monograph 102). Environment Res. 2018; 167: 673-683.
Radziwon-Balicka A, et al. Trombosits increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. British Journal of Pharmacology. 2012;167(4):787–804.
Aminian A, KF, Mirsharifi R, Alibakhshi A, Dashti H, Jahangiri Y, Safari S, Ghaderi H, Noaparast M, Hasani SM, Mirsharifi A. Significance of kadar trombosit in esophageal carcinomas. Saudi J Gastroenterol. 2011;17(2):134–137
Cho MS, et al. Trombosits increase the proliferation of ovarian cancer cells. Blood. 2012.
Matsuo K, Nishimura M, Komurov K et al. Trombosit-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol, 2014: 132:166–175.
Eggemann H, Ehricke J, Ignatov T, Fettke F, Semczuk A, Costa SD, et al. Kadar trombosit after kemoterapi is a predictor for outcome for ovarian Cancer patients. Cancer Investig. 2015;33(5):193–6. https://doi.org/10.3109/ 07357907.2015.1020384.
Henriksen, J.R., Nederby, L., Donskov, F. et al. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with kemoterapi. J Ovarian Res 13, 59 (2020). https://doi.org/10.1186/s13048-020-00661-4.
Murta M and Candido E. Systemic Leukocyte Alterations in Cancer and their Relation to Prognosis. The Open Cancer Journal, 2008, 2, 53-58 53.
Kyeong A, S. et al. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma : A retrospective cohort study’, Gynecologic Oncology. Elsevier Inc., 2014: 132(3), pp. 551–555. doi: 10.1016/j.ygyno.2014.01.010.
Nasser SM, Choudry UH, Nielsen GP, Ott MJ. A leukemoid reaction in a patient with a dedifferentiated liposarcoma. Surgery 2001;129:765–7.
Dicato M, Plawny L, Diederich M (2010). Anemia in cancer. Ann Oncol, 21, 167-72.
Canzler, U. et al. Prognostic role of thrombocytosis in rekuren ovarian cancer: a pooled analysis of the AGO Study Group’, Archives of Gynecology and Obstetrics, 2020. doi: 10.1007/s00404-020-05529-y.
Menter, D.G.; Tucker, S.C.; Kopetz, S.; Sood, A.K.; Crissman, J.D.; Honn, K.V. Trombosits and cancer: A casual or causal relationship: Revisited. Cancer Metastasis Rev. 2014, 33, 231–269. [CrossRef] [PubMed]
Demers M, Ho-TinNoe B, Schatzberg D, Yang JJ, Wagner DD. Increased efficancy of breast cancer kemoterapi in thrombocytopenic mice. Cancer Res. 2011; 71(5): 1540–1509.
Eggemann H, Ehricke J, Ignatov T, Fettke F, Semczuk A, Costa SD, et al. Kadar trombosit after kemoterapi is a predictor for outcome for ovarian Cancer patients. Cancer Investig. 2015;33(5):193–6. https://doi.org/10.3109/ 07357907.2015.1020384.
Hanahan, D.H., dan Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Review, 2011; 144(5).
Noviyani, R. et al. (2019) ‘Effect of paclitaxel-cisplatin kemoterapi towards hemoglobin , trombosit , and leukocyte levels in epithelial ovarian cancer patients’, 9(01), pp. 104–107. doi: 10.7324/JAPS.2019.90115.
DOI: http://dx.doi.org/10.24198/obgynia.v5i1.323
Refbacks
- There are currently no refbacks.
_CROSREF22.jpg)
